The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes of IDH1/2 mutant AML patients treated with IDH1/2 inhibitors: A single institutional experience.
 
Constantine Nick Logothetis
No Relationships to Disclose
 
Chetasi Talati
No Relationships to Disclose
 
Gregoire Calon
No Relationships to Disclose
 
Nathan P Horvat
No Relationships to Disclose
 
Virginia Olivia Volpe
No Relationships to Disclose
 
Nicole D. Vincelette
No Relationships to Disclose
 
Andrew T. Kuykendall
No Relationships to Disclose
 
Onyee Chan
No Relationships to Disclose
 
David Andrew Sallman
Consulting or Advisory Role - Abbvie; Agios; Aprea AB; Bristol-Myers Squibb; Celyad; Gilead Sciences; Intellia Therapeutics; Kite, a Gilead company; Magenta Therapeutics; Novartis; Syndax
Speakers' Bureau - Agios; Bristol-Myers Squibb; Incyte
Research Funding - Celgene; Jazz Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Intellectual Property Patent for LB-100 in MDS
 
Eric Padron
Honoraria - Blueprint Medicines; Stemline Therapeutics
Speakers' Bureau - Novartis; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Incyte (Inst); Kura Oncology (Inst)
 
Kendra L Sweet
Honoraria - Astellas Pharma
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis
Research Funding - Incyte (Inst)
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Abbvie; Acceleron Pharma; Bristol-Myers Squibb; Geron; Jazz Pharmaceuticals; Novartis
Speakers' Bureau - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Jazz Pharmaceuticals
 
Ling Zhang
No Relationships to Disclose
 
Jeffrey E. Lancet
Stock and Other Ownership Interests - Arvinas (I)
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; BerGenBio; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; ElevateBio; Jazz Pharmaceuticals; Millennium; Novartis
Research Funding - Pfizer (Inst)
 
Seongseok Yun
No Relationships to Disclose